Susan Moran
Vermögen: 973 $ am 31.08.2026
Vermögen: 973 $ am 31.08.2026
Susan Moran is currently an Independent Director at Crescent Biopharma, Inc. since 2024, BioAtla, Inc. since 2020, and Tyra Biosciences, Inc. since 2024.
Former positions include Chief Medical Officer at Rayzebio, Inc. from 2021 to 2024, Chief Medical Officer at QED Therapeutics, Inc. from 2018 to 2021, Vice President & Head-Clinical Development at Puma Biotechnology, Inc. from 2016 to 2018, Medical Director at Millennium Pharmaceuticals, Inc. from 2011 to 2014, and Senior Medical Director at Genzyme Therapeutics Ltd. from 2007 to 2011.
Education includes undergraduate studies at the University of Virginia, and graduate studies at Duke University and the University of Pennsylvania Medical Center.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BIOATLA, INC. 0,03 % | 18.05.2026 | 576 ( 0,03 % ) | 973 $ | 31.08.2026 |
TYRA BIOSCIENCE, INC -.--% | 28.05.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
-.--% | 02.06.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOATLA, INC. | Direktor/Vorstandsmitglied | 01.12.2020 |
| TYRA BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 07.05.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
| RAYZEBIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2024 |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2021 |
| PUMA BIOTECHNOLOGY, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2018 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2014 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2011 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
University of Virginia
University of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
BioAtla, Inc.
BioAtla, Inc. BiotechnologyHealth Technology Develops novel monoclonal antibody and protein therapeutic products | Health Technology |
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
University of Pennsylvania Medical Center
University of Pennsylvania Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Tyra Biosciences, Inc.
Tyra Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops cancer treatment drug therapies | Health Technology |
Rayzebio, Inc.
Rayzebio, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapeutics for cancer treatment | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen